全部文献期刊会议图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Antoine Hollebecque , Christophe Massard ...
来源:[J].Cancer Chemotherapy and Pharmacology(IF 2.795), 2017, Vol.79 (6), pp.1257-1265
摘要:This phase I trial evaluated the safety and tolerability of milciclib, an inhibitor of multiple cyclin-dependent kinases and tropomycin receptor kinase A, in combination with gemcitabine in patients with refractory solid tumors.
作者:Antoine Hollebecque , Charles Honoré ...
来源:[J].Annals of Surgical Oncology(IF 4.12), 2017, Vol.24 (12), pp.3640-3646
摘要:This report aims to describe preliminary results concerning secondary resectability after bidirectional chemotherapy for initially unresectable malignant peritoneal mesothelioma (MPM).
作者:Antoine Hollebecque , Etienne Chatelut ...
来源:[J].BMC Cancer(IF 3.333), 2017, Vol.17 (1)
摘要:Vascular endothelial growth factor (VEGF) directed therapies are being used in a large number of advanced tumors. Metastatic renal cell carcinoma (mRCC) is highly dependent on the VEGF pathway; VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKI) and humanized VEGF monoclonal a...
作者:Antoine Hollebecque , Dominique Hillaire-Buys
来源:[J].European Journal of Cancer(IF 5.061), 2020, Vol.129, pp.32-40
摘要:Abstract(#br)Background(#br)5-Fluorouracil (5-FU)-induced hyperammonaemic encephalopathy is a rare but serious 5-FU adverse drug reaction (ADR). Given the growing number of cancers treated with 5-FU and the paucity of data regarding this ADR, we performed a retrospective nat...
作者:Antoine Hollebecque , Olivier Lambotte ...
来源:[J].European Journal of Cancer(IF 5.061), 2020, Vol.129, pp.71-79
摘要:Abstract(#br)Background(#br)Aging is an important risk factor for cancers and is associated with poor prognosis. Weakness of the immune system, also called immunosenescence may occur with older age. The impact of aging on efficacy and safety of immune checkpoint blockers, su...
作者:Antoine Hollebecque , Andrea Varga ...
来源:[J].European Journal of Cancer(IF 5.061), 2020, Vol.130, pp.39-50
摘要:Abstract(#br)Purpose(#br)We investigated the activities of an ImmunoTOX board, an academic, multidisciplinary group of oncologists and organ specialists that adopts a real-life, case-by-case approach in the management of patients with immune-related adverse events (irAEs).(#br)Ex...
作者:... Valérie Boige , Antoine Hollebecque , David Malka
来源:[J].Seminars in Oncology(IF 4.327), 2017
摘要:Abstract(#br)The last two decades have seen intensive efforts devoted to the development of compounds that target angiogenesis for the treatment of metastatic colorectal cancer (mCRC). In this review, we describe supporting evidence and ongoing development of angiogenesis inhibit...
作者:Antoine Hollebecque , Alberto Carmona ...
来源:[J].European Journal of Cancer(IF 5.061), 2017, Vol.84, pp.212-218
摘要:Abstract(#br)Introduction(#br)Life expectancy evaluation is crucial when selecting patients who may benefit from phase I studies. The Royal Marsden Hospital (RMH) prognostic score, based on three objective variables (number of metastatic sites, lactate dehydrogenase (LDH) an...
作者:Antoine Hollebecque , Charlotte Peugniez ...
来源:[J].Clinical Colorectal Cancer(IF 1.8), 2018, Vol.17 (1), pp.e99-e107
摘要:Abstract(#br)Background(#br)We studied the relationship between intermediate criteria and overall survival (OS) in metastatic colorectal cancer (mCRC) patients who received first-line chemotherapy with bevacizumab.(#br)Patients and Methods(#br)We assessed OS, progression-free sur...
作者:... Michel Ducreux , Jean-Charles Soria , Antoine Hollebecque
来源:[J].European Journal of Cancer(IF 5.061), 2017, Vol.87, pp.122-130
摘要:Abstract(#br)Background(#br)Recommended treatments of patients with advanced biliary tract cancer (aBTC) are limited to one chemotherapy doublet. Nevertheless, efficacy of treatment personalisation for aBTCs is supported by accumulating evidences but remains to be evaluated....

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×